

1. Andersen G, Christrup L, Sjoegren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. *J Pain Symptom Manage* 2003;25:74-91.
2. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. *Pain* 1988;33:149-160.
3. Bates JJ, Foss JF, Murphy DB. Are peripheral opioid antagonist the solution to opioid side effects? *Anesth Analg* 2004;98:116-122.
4. Befort K, Filliol D, Decailot FM, et al. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. *J Biol Chem* 2001;276:3130-3137.
5. Bergen AW, Kokoszka J, Peterson R, et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. *Mol Psychiatry* 1997;2:490-494.
6. Beyer A, Koch T, Schröder H, et al. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. *J Neurochem* 2004;89:553-560.
7. Bolan EA, Pan YX, Pasternak GW. Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm. *Synapse* 2004;51:11-18.
8. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. *Proc Natl Acad Sci U-S-A* 1998;95:9608-9613.
9. Brunk SF, Delle M. Morphine metabolism in man. *Clin Pharmacol Ther* 1994;16:51-57.
10. Caraco Y, Maroz Y, Davidson E. Variability in alfentanil analgesia maybe attributed to polymorphism in the mu-opioid receptor gene. *Clin Pharmacol Ther* 2001;69:63.
11. Carter BD, Medzihradsky F. Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain. *Proc Natl Acad Sci-U-S-A* 1993; 90:4062-4066.
12. Chen Y, Mestek A, Liu J, et al. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. *Mol Pharmacol* 1993;44:8-12.
13. Cherny NI. Opioid analgesics: Comparative features and prescribing guidelines. *Drugs* 1996;51:713-737.
14. Christo PJ. Opioid effectiveness and side effects in chronic pain. *Anesthesiol Clin North America* 2003;21:699-713.
15. Compton P, Geschwind DH, Alarcon M. Association between human mu- opioid receptor gene polymorphism, pain tolerance and opioid addiction. *Am J Med Genet* 2003;121:76-82.

16. Cowan DT, Wilson-Barnett J, Griffiths P, et al. A survey of chronic noncancer pain patients prescribed opioid analgesics. *Pain Med* 2003;4:340-351.
17. Crowley JJ, Oslin DW, Patkar AA, et al. A genetic association study of the mu opioid receptor and severe opioid dependence. *Psychiatr Genet* 2003;13:169-173.
18. Deutsche Krebsgesellschaft: Kurzgefasste Interdisziplinäre Leitlinien 2002;3. Auflage 2002
19. Diener C, Maier CH. *Das Schmerztherapiebuch* (2003), Urban und Fischer Verlag, München, Jena 2. Auflage:356
20. Dray A. Inflammatory mediators of pain. *Br J Anaesth* 1995;75:125-131.
21. Engel GL. The need for a new medical model: a challenge for biomedicine. *Science* 1977;196:129-136.
22. Evans CJ, Keith DE, Morrison H, et al. Cloning of a delta opioid receptor by functional expression. *Science* 1992;258:1952-1955.
23. Fallon M, O'Neill B. ABC of palliative care. Constipation and diarrhoea. *BMJ* 1997;315:1293-1296.
24. Fernandez E, Turk DC. The scope and significance of anger in the experience of chronic pain. *Pain* 1995;61:165-175.
25. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. *Neuron* 2001;32:829-839.
26. Franke P, Wang T, Nothen MM, et al. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence *Am J Med Genet* 2001;105:114-119.
27. Freye E, Latasch L. Development of opioid tolerance molecular mechanisms and clinical consequences. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2003;38:14-26.
28. Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies and allele frequencies in alcohol- and drug-dependent subjects. *Mol Psychiatry* 1999;4:476-483.
29. Goldsmith T, Shapira N, Keck P. Rapid remission of OCD with tramadol hydrochloride. *Am J Psychiatry* 1999;156:660-661.
30. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. *Clin Pharmacokinet* 1993;24:344-354.
31. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, et al. Outcome of chronic opioid therapy for non-cancer pain. *J Pain Symptom Manage* 1998;15:185-194.

32. Hernandez-Avila CA, Wand G, Luo X, et al. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). *Am J Med Genet B Neuropsychiatr Genet* 2003;118:60-65.
33. Hirota T, Ieiri I, Takane H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. *Drug Metab Dispos* 2003;31:677-680.
34. Hoehe MR, Kopke K, Wendel B, et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. *Hum Mol Genet* 2000;9:2895-2908.
35. Huskisson EC. Measurement of pain. *J Rheumatol* 1982;9:768-769.
36. Insel T, Pickar D. Naloxone administration in obsessive-compulsive disorder: Report of two cases. *Am J Psychiatry* 1983;140:1219-1220.
37. Inturrisi CE, Jamison R. Clinical pharmacology of opioids for pain. *Clin J Pain* 2002;18:3-13.
38. Jorm AF, Prior M, Sanson A, et al. Lack of association of a single-nucleotide polymorphism of the mu-opioid receptor gene with anxiety-related traits: results from a cross-sectional study of adults and a longitudinal study of children. *Am J Med Genet* 2002;114:659-664.
39. Kanjhan R. Opioids and Pain. *Clin Exp Pharmacol Physiol* 1995;22:397-403.
40. Keuler D, Altemus M, Michelson D, et al. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. *Biol Psychiatry* 1996;40:154-156.
41. Kieffer BL, Befort K, Gaveriaux-Ruff C, et al. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. *Proc Natl Acad Sci U-S-A* 1994;91:1193.
42. Kim SG, Kim CM, Kang DH, et al. Association of functional opioid receptor genotypes with alcohol dependence in Koreans. *Alcohol Clin Exp Res* 2004;28:986-990.
43. Kitanaka N, Sora I, Kinsey S, et al. No heroin or morphine 6beta-glucuronide analgesia in mu-opioid receptor knockout mice. *Eur J Pharmacol* 1998;355:R1-R3.
44. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. *Acta Anaesthesiol Scand* 2004;48:1232-1239.
45. Lee NM, Smith AP. Opioid receptor polymorphisms and opioid abuse. *Pharmacogenomics* 2002;3:219-227.
46. Li T, Liu X, Zhu HZ et al. Association analysis of polymorphism in the μ -opioid gene and heroin abuse in Chinese subjects. *Addict Biol* 2000;5:181-185

47. Loh HH, Smith AP. Molecular characterization of opioid receptors. *Annu Rev Pharmacol Toxicol* 1990;30:123-147.
48. Lotsch J, Freyenhagen R, Geisslinger G. Are polymorphisms in the mu-opioid receptor important for opioid therapy? *Schmerz* 2005;19:378-382, 384-385.
49. Lotsch J, Skarke C, Grosch S, et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. *Pharmacogenetics* 2002;12:3-9.
50. Lotsch J, Skarke C, Schmidt H, et al. Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. *Clin Pharmacol Ther* 2002;72:151-162.
51. Lotsch J, Weiss M, Ahne G, et al. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. *Anesthesiology* 1999;90:1026-1038.
52. Lotsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? *Anesthesiology* 2002;97:814-819.
53. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. *J Pharmacol Exp Ther* 1976;197:517-532.
54. Mayer P, Höllt V. Allelic and somatic variations in the endogenous opioid system of humans. *Pharmacol Ther* 2001;3:167-177
55. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *J Pain* 2003;4:231-256.
56. Miller GM, Bendor J, Tiefenbacher S, et al. A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. *Mol Psychiatry* 2004;9:99-108.
57. Mizoguchi H, Wu HE, Narita M, et al. Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 gene. *J Pharmacol Sci* 2003;93:423-429.
58. Mogil JS: The genetic mediation of individual differences in sensitivity to pain and its inhibition. *Proc Natl Acad Sci-U-S-A* 1999;96:7744-7751.
59. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. *Arthritis Res Ther* 2005;7:R1046-1051.
60. Ohmori O, Shinkai T, Hori H, et al. Polymorphisms of mu and delta opioid receptor genes and tardive dyskinesia in patients with schizophrenia. *Schizophr Res* 2001;52:137-138.

61. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. *Neuropsychopharmacology* 2003;28:1546-1552.
62. Pan YX, Xu J, Mahurter L, et al. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. *Proc Natl Acad Sci U-S-A* 2001;98:14084-14089.
63. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. *J Pharmacol Exp Ther* 1992;260:275-285.
64. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. *Neurology* 2002;59:1015-1021.
65. Romano JM, Turner JA. Chronic pain and depression: does the evidence support a relationship? *Psychol Bull* 1985;97:18-34.
66. Rommelspacher H, Smolka M, Schmidt LG, et al. Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. *Alcohol* 2001;24:129-135.
67. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U-S-A* 1977;74:5463.
68. Schinka JA, Town T, Abdullah L, et al. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. *Mol Psychiatry* 2002;7:224-228.
69. Shapira NA, McConville BJ, Pagnucco ML, et al. Novel use of tramadol hydrochloride in the treatment of Tourette's syndrome. *J Clin Psychiatry* 1997;58:174-175.
70. Shi J, Hui L, Xu Y, et al. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. *Hum Mutat* 2002;19:459-460.
71. Skarke C, Kirchof A, Geisslinger G, et al. Comprehensive mu-opioid-receptor genotyping by pyrosequencing. *Clin Chem* 2004;50:640-644.
72. Sora I, Takahashi N, Funada M, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. *Proc Natl Acad Sci U-S-A* 1997;94:1544-1549.
73. Szeto CY, Tang NL, Lee DT, et al. Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. *Neuroreport* 2001;12:1103-1106.
74. Tan EC, Tan CH, Karupathivan U, et al. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. *Neuroreport* 2003;14:569-572.

75. Tassain V, Attal N, Fletcher D, et al. Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. *Pain* 2003;104:389-400.
76. Terenius L. Stereospecific uptake of narcotic analgesics by a subcellular fraction of the guinea-pig ileum. A preliminary communication. *Ups J Med Sci* 1973;78:150-152.
77. Town T, Abdullah L, Crawford F, et al. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. *Am J Med Genet* 1999;88:458-461.
78. Uhl GR, Childers S, Pasternak GW. An opiate-receptor gene family reunion. *Trends Neurosci* 1994;17:89-93.
79. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. *Proc Natl Acad Sci U-S-A* 1999;96:7752-7755.
80. Urraca N, Camarena B, Gómez-Caudillo L, et al. μ Opioid Receptor Gene as a Candidate for the Study of Obsessive Compulsive Disorder With and Without Tics *Am J Med Genet* 2004;127B:94-96.
81. Wand GS, McCaul M, Yang X, et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade *Neuropsychopharmacology* 2002;26:106-114.
82. Wang JB, Imai Y, Eppler CM, et al. mu opiate receptor: cDNA cloning and expression. *Proc Natl Acad Sci U-S-A* 1994;90:10230-10234.
83. Wei LN, Loh HH. Regulation of opioid receptor expression. *Curr Opin Pharmacol* 2002;2:69-75.
84. Wendel B, Hoehe MR. The human mu opioid receptor gene: 5' regulatory and intronic sequences. *J Mol Med* 1998;76:525-532.
85. Wilkie H, Osei-Lah A, Chioza B, et al. Association of mu-opioid receptor subunit gene and idiopathic generalized epilepsy. *Neurology* 2002;59:724-728.
86. Yuan CS, Foss JF. Antagonism of gastrointestinal opioid effects. *Reg Anesth Pain Med* 2000;25:639-642.
87. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. *J Pain Symptom Manage* 1992;7:69-77.
88. Zimmermann M, Rittmeister M. Postoperative Schmerztherapie in der Orthopädie. *Orthopäde* 2003;32:1110-1119.